Overview
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
Status:
Recruiting
Recruiting
Trial end date:
2021-10-01
2021-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in male and female participants with performance anxiety.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Vanda Pharmaceuticals
Criteria
Inclusion Criteria:- Ability and willingness to provide written informed consent.
- Sufficiently fluent in English to participate in the trial.
- Male and female patients aged 18-70 years (inclusive).
Exclusion Criteria:
- Lifetime history of bipolar disorder, schizophrenia, psychosis, seizures, delusional
disorders or obsessive-compulsive disorder.
- Current or planned pregnancy or nursing during the trial period.
- A positive test for substances of abuse.